Embera NeuroTherapeutics’ Chief Medical Officer, Michael Detke, to Moderate Panel on the Neuroscience of Addiction at BIO CEO & Investor Conference
BOSTON, Mass. and SHREVEPORT, La. – February 12, 2018 – Embera NeuroTherapeutics today announced that Michael Detke, M.D., Ph.D., Embera’s Chief Medical Officer, will moderate the “Neuroscience of Addiction: Levers to Attack the Opioid Abuse Crisis” panel at 2018 BIO CEO & Investor Conference.
EMB-001 is a patented combination product comprising two FDA-approved medications, the cortisol synthesis inhibitor metyrapone and the benzodiazepine oxazepam. The innovation is based on insights into the physiologic responses to stress in addiction. EMB-001 is thought to act by mechanisms distinct from those of existing addiction treatments and is hypothesized to reduce the increased activity in the stress response system induced by cues that contribute to the acquisition and maintenance of addiction.
EMB-001 may potentially reduce the cravings and loss of control that drive addiction by uniquely targeting multiple pathways, thereby possibly maximizing potential efficacy as well as minimizing safety and tolerability concerns. Therapies that reduce cravings and relapse and thus result in long-term abstinence and recovery would be significant contributions to the treatment of a broad range of addictions.
About Embera NeuroTherapeutics
Embera NeuroTherapeutics, Inc. is a clinical-stage pharmaceutical company focused on treating a broad range of addictions where the major clinical challenge is a limited range of effective therapies. Embera is developing a novel drug combination (EMB-001) targeting specific brain functions related to stress responses that drive craving and relapse associated with these disorders. Embera is advancing EMB-001 development programs in cocaine use disorder and smoking cessation. www.emberaneuro.com
Bob Linke President and CEO
Embera NeuroTherapeutics, Inc.